Nanobiotix
Paris
France
206 articles about Nanobiotix
-
NANOBIOTIX to Announce Third Quarter 2022 Financial Results on November 9, 2022
10/27/2022
NANOBIOTIX announced that it will report its financial results for the third quarter ended September 30, 2022, on Wednesday, November 9, 2022, after the close of the US market.
-
NANOBIOTIX Executes Definitive Agreement to Restructure Existing Loan With the European Investment Bank
10/18/2022
NANOBIOTIX announced execution of a final agreement with the European Investment Bank to re-align approximately €30.7 million in outstanding debt obligations with the Company’s expected development and commercialization timelines.
-
Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022
9/28/2022
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, provided an update on operational progress and announced its half year financial results for the six-month period ended June 30, 2022.
-
Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022
9/22/2022
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will report its financial results for half-year ending June 30, 2022, on Wednesday, September 28, 2022, after the close of the US market.
-
Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy
9/21/2022
NANOBIOTIX today announced determination of the recommended phase 2 dose (RP2D) of NBTXR3 in combination with pembrolizumab or nivolumab for the treatment of patients suffering from inoperable locoregional recurrent (LRR) or recurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) that is resistant to prior immunotherapy.
-
Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024
9/12/2022
NANOBIOTIX announced reaching an agreement in principle to restructure €30.7 million in outstanding debt obligations related to the Company’s 2018 loan agreement with the European Investment Bank.
-
NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer
9/7/2022
NANOBIOTIX (Euronext: NANO – Nasdaq: NBTX), and LianBio (Nasdaq: LIAN), today announced randomization of the first patient in Asia in NANORAY-312, a global Phase 3 registrational trial evaluating NBTXR3 for the treatment of elderly patients with locally advanced head and neck squamous cell carcinoma (“LA-HNSCC”) who are ineligible for platinum-based chemotherapy.
-
NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in Life Sciences
9/6/2022
NANOBIOTIX announced that Laurent Levy, Co-Founder and Chief Executive Officer of Nanobiotix, has been named to the PharmaVoice 100 list of the most inspiring people in the life sciences.
-
Nanobiotix to Present During the H.C. Wainwright Global Investment Conference in September 2022
8/31/2022
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), today announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in the H.C. Wainwright 24th Annual Global Investment Conference to take place in-person in New York and virtually September 12th-14th 2022.
-
Half-year Report on the Nanobiotix Liquidity Contract With Gilbert Dupont
7/13/2022
NANOBIOTIX, a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, issued the Half-Year report on its liquidity contract with Gilbert Dupont.
-
NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications
6/5/2022
NANOBIOTIX announced the reporting of new data at the 2022 Annual Meeting of the American Society for Clinical Oncology featuring potential first-in-class radioenhancer NBTXR3 in combination with concurrent chemoradiation for the treatment of head and neck cancer and rectal cancer.
-
NANOBIOTIX Annual Shareholders’ General Meeting to Be Held on June 23, 2022
6/2/2022
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that its Annual Combined Shareholders General Meeting will be held on June 23, 2022.
-
NANOBIOTIX Provides First Quarter Operational and Financial Update
5/18/2022
NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the "Company"), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced operational progress, cash position (unaudited) for the first quarter of 2022, and extension of operating runway into Q4 2023.
-
NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022
5/17/2022
NANOBIOTIX announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in the Jefferies Healthcare Conference in June 2022.
-
NANOBIOTIX to Participate in Two Upcoming Investor Conferences
5/11/2022
Regulatory News: NANOBIOTIX, a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in the following conferences.
-
NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022
5/4/2022
NANOBIOTIX announced that it will report its financial results for the first quarter of 2022 ending March 31, 2022, on Wednesday, May 18, 2022, after the close of the US market.
-
New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022 ASCO Annual Meeting
5/2/2022
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the presentation of three abstracts featuring potential first-in-class radioenhancer NBTXR3 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7.
-
NANOBOTIX: New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, LAG-3, and TIGIT When Combined With Radiotherapy-Activated NBTXR3
4/11/2022
NANOBOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced new data from an open-label preclinical study evaluating the combination of first-in-class radioenhancer, NBTXR3, with the triple blockade of PD-1, LAG-3, and TIGIT (“Combination therapy”).
-
NANOBIOTIX Announces Filing of the 2021 Universal Registration Document and the 2021 Annual Report on Form 20-F
4/8/2022
NANOBIOTIX announced the filing of its universal registration document for the financial year ended December 31, 2021 with the French financial market authority, as well as of the Annual Report on Form 20-F for the financial year ended December 31, 2021 with the U.S. Securities and Exchange Commission.
-
NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial Results
3/30/2022
NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, provided an update on operational progress and reported financial results1 for the year ended December 31, 2021.